SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: tktom who wrote (4029)12/11/2015 8:43:47 PM
From: Biomaven  Respond to of 4474
 
Read the whole post:

siliconinvestor.com



To: tktom who wrote (4029)12/11/2015 9:24:26 PM
From: mulanoon2007  Read Replies (1) | Respond to of 4474
 
FWIW, alectinib took 27 months from breakthrough designation (Sep 2013) to approval. It is 15 months since BRIG received breakthrough designation (28 months since their first application was denied). I believe it not unreasonable for BRIG to receive a license at the end of 2016; 15 months after the last patient data for endpoint analysis were collected.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News